Pharmaceuticals are seen as one of the classic defensive stocks, with the reasoning that people still get sick no matter how the economy is performing. They have faltered in recent years, however, as investors worry about new legislation in the U.S., by far the world’s biggest market for medicines, and the lack of new products coming through to replace blockbuster drugs that are coming off patent.
“There are negative headwinds for the sector, with government spending and generics the two big ones,” Nelson said. “We think you get to the patent cliff in (the fourth-quarter) this year so you’ll get some of that bad news out of the way.”
He added that growth in emerging markets would set off some of the negative headwinds, and pointed to strong dividend yields for the bigger pharma companies.
“In the more cyclical space, we still like some energy companies and bits of tech, particularly software,” he added.
Additional News: Cramer’s Ultimate Growth Stocks for 2012
Additional Views: Calling Shenanigans on Amylin Pharma
CNBC Data Pages:
Disclosure information for Nick Nelson and his company was not immediately available.